Company Pulls Three Doses of Extended-Release Ritalin
Published Date: 6/18/2026
Notice
Summary
SpecGx LLC has asked the FDA to withdraw its approval for three strengths (27 mg, 36 mg, and 54 mg) of its methylphenidate extended-release tablets, effective June 18, 2026. This means these specific versions of the medicine will no longer be allowed on the market. Patients and pharmacies using these doses should look for alternatives, but no extra costs or penalties are mentioned.
Analyzed Economic Effects
2 provisions identified: 0 benefits, 2 costs, 0 mixed.
Three methylphenidate ER strengths withdrawn
If you use SpecGx's methylphenidate hydrochloride extended-release (ER) tablets in 27 mg, 36 mg, or 54 mg strengths, those specific products are no longer allowed on the market starting June 18, 2026. Patients and pharmacies using these exact strengths should seek alternative products or doses.
Interstate distribution becomes illegal for withdrawn products
As of June 18, 2026, distributing SpecGx's methylphenidate HCl ER tablets in 27 mg, 36 mg, or 54 mg into interstate commerce without an approved application is illegal and may lead to regulatory action under sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act. Pharmacies, distributors, or sellers handling these specific products must stop interstate distribution to avoid enforcement.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-19281, Agency Information Collection Activities; Proposed Collection; Comment Request; Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002
The FDA wants your thoughts on keeping the rules for telling them about imported food before it arrives. This affects food importers who must keep sharing info to keep our food safe. You’ve got until November 20, 2026, to send in your comments—no cost changes, just a chance to help shape the process!
2026-19284, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Orphan Drugs
The FDA is asking for public feedback on their plan to keep collecting info about orphan drugs—special medicines for rare diseases. This helps make sure drug makers follow rules and get the right approvals, keeping the process smooth and fair. Comments are open until October 21, 2026, and this review won’t cost anyone extra but keeps important protections in place.
Previous / Next Documents
Previous: 2026-12235, Advisory Committee; Science Board to the Food and Drug Administration; Renewal
The FDA is renewing its Science Board for two more years, keeping expert advice flowing to help ensure safe and effective drugs and products. This renewal affects scientists and public health folks who guide the FDA’s big decisions, with the new term lasting until June 26, 2028. No extra costs or delays are expected—just more smart brains working for your health!
Next: 2026-12237, Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Current Good Manufacturing Practice Regulations for Type A Medicated Articles and Medicated Feeds
The FDA is updating how companies that make special animal medicines and feeds keep their records and follow quality rules. This affects manufacturers of Type A medicated articles and medicated feeds, helping ensure safe and reliable products for animals. Comments on these changes are open until July 20, 2026, and the updates aim to keep things clear without adding extra costs.